OncoSec's (ONCS) ImmunoPulse Il-12 Granted Fast Track Status by FDA for Metastatic Melanoma Following Progression on Merck's (MRK) KEYTRUDA or Bristol-Myers Squibb's (BMY) Opdivo

Source Link:

http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html